scholarly journals Metastatic Cervical Carcinoma with High-Risk Human Papillomavirus (HPV) Positive and P16/ Ki-67 Positive in a 28 Year-Old Female That Did Not Meet the Current Screening Guidelines

2015 ◽  
Vol 2 (2) ◽  
pp. 49-51
Author(s):  
Stephenie Matosich ◽  
◽  
Sarah Hall ◽  
2019 ◽  
Vol 64 (1-2) ◽  
pp. 63-70
Author(s):  
Andrea D. Olivas ◽  
Julieta E. Barroeta ◽  
Ricardo R. Lastra

The association between high-risk genotypes of human papillomavirus (hr-HPV) and cervical cancer is well established. As hr-HPV testing is rapidly becoming a part of routine cervical cancer screening, either in conjunction with cytology or as primary testing, the management of hr-HPV-positive women has to be tailored in a way that increases the detection of cervical abnormalities while decreasing unnecessary colposcopic biopsies or other invasive procedures. In this review, we discuss the overall utility and strategies of hr-HPV testing, as well as the advantages and limitations of potential triage strategies for hr-HPV-positive women, including HPV genotyping, p16/Ki-67 dual staining, and methylation assays.


2011 ◽  
Vol 07 (04) ◽  
pp. 243
Author(s):  
Channa E Schmeink ◽  
Leon FAG Massuger ◽  
Willem JG Melchers ◽  
Ruud LM Bekkers ◽  
◽  
...  

Primary screening based on detection of human papillomavirus (HPV) has proved to be more sensitive than cytology for the detection of high-grade cervical intraepithelial neoplasia (CIN). Self-sampling for specimen collection may also improve the participation rate, especially in the non-responder group. However, HPV is highly prevalent and therefore HPV detection has a lower specificity in cervical cancer screening than cytology. In addition to the clinically validated HPV test, HPV dynamics should be taken into account. It is important to identify women with a chronic productive infection likely to cause, or to already have caused, high-grade CIN or cervical carcinoma, and to limit overtreatment of women with a transient infection. Furthermore, the introduction of the HPV vaccine is likely to lower the incidence of CIN and cervical carcinoma, which will lower the positive predictive value of cervical cancer screening. This potential impact needs to be taken into account when planning for future screening guidelines.


2009 ◽  
Vol 132 (3) ◽  
pp. 378-390 ◽  
Author(s):  
Pablo Conesa-Zamora ◽  
Asunción Doménech-Peris ◽  
Francisco J. Orantes-Casado ◽  
Sebastián Ortiz-Reina ◽  
Laura Sahuquillo-Frías ◽  
...  

2011 ◽  
Vol 50 (1) ◽  
pp. 46-49 ◽  
Author(s):  
Jiri Slama ◽  
Marcela Drazdakova ◽  
Pavel Dundr ◽  
Daniela Fischerova ◽  
Michal Zikan ◽  
...  

2007 ◽  
Vol 105 (2) ◽  
pp. 418-426 ◽  
Author(s):  
Mahmood Manavi ◽  
Gernot Hudelist ◽  
Anneliese Fink-Retter ◽  
Daphne Gschwandtler-Kaulich ◽  
Kerstin Pischinger ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document